Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab beta plus FOLFOX first-line for unresectable metastatic RAS/BRAF wild-type colorectal cancer
ChiCTR2500101590Phase 2Not yet recruiting
- Sponsor
- Tianjin People's Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Tianjin People's Hospital. Primary endpoint: Objective Response Rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2500101590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101590.